Fala, L. (2016). Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Heart Failure. Am Health Drug Benefits.
Styl cytowania ChicagoFala, Loretta. "Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Heart Failure." Am Health Drug Benefits 2016.
Styl cytowania MLAFala, Loretta. "Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Heart Failure." Am Health Drug Benefits 2016.
Uwaga: Te cytaty mogą odróżniać się od wytycznej twojego fakultetu..